FDA Committee Votes Down Janssen’s Plivensia Arthritis Drug

0
42

An FDA advisory committee voted 12-to-1 against recommending approval of Janssen’s Plivensia (sirukumab) in treating rheumatoid arthritis, saying its safety profile raised too many concerns.

Comments

comments